Evidence map›Paper›PMID 41565922›Full record

ArticleBrain tumor pathology2026

Diverse NF2 alterations in cranial schwannomas: a two-case series of germline whole-gene deletion and somatic in-frame deletion.

Kohei Nakamura, Ryota Tamura, Junki Sogano, Masahiro Yo, Kosuke Karatsu, Thinh Huy Nguyen, Reika Takamatsu, Kumiko Misu, Ippei Fukada, Kenjiro Kosaki and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Brain tumor pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Kohei NakamuraCenter for Cancer Genomics, Keio University School of Medicine, Shinjuku-Ku, Tokyo, 160-8582, Japan.
Ryota TamuraDepartment of Neurosurgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan. moltobello-r-610@keio.jp.
Junki SoganoDepartment of Neurosurgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan.
Masahiro YoDepartment of Neurosurgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan.
Kosuke KaratsuDepartment of Neurosurgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan.
Thinh Huy NguyenCenter for Cancer Genomics, Keio University School of Medicine, Shinjuku-Ku, Tokyo, 160-8582, Japan.
Reika TakamatsuCenter for Cancer Genomics, Keio University School of Medicine, Shinjuku-Ku, Tokyo, 160-8582, Japan.
Kumiko MisuCenter for Medical Genetics, Keio University School of Medicine, Shinjuku-Ku, Tokyo, 160-8582, Japan.
Ippei FukadaGenomic Medicine, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-Ku, Tokyo, 135-8550, Japan.
Kenjiro KosakiCenter for Medical Genetics, Keio University School of Medicine, Shinjuku-Ku, Tokyo, 160-8582, Japan.
Takayuki UenoBreast Oncology Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-Ku, Tokyo, 135-8550, Japan.
Hiroshi NishiharaCenter for Cancer Genomics, Keio University School of Medicine, Shinjuku-Ku, Tokyo, 160-8582, Japan.
Masahiro TodaDepartment of Neurosurgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan.

Funding

Japan Agency for Medical Research and Development JP23ck0106872Japan Agency for Medical Research and Development JP24ck0106872
6 · The paper itself

Abstract

NF2-related schwannomatosis is a tumor predisposition syndrome caused by diverse NF2 alterations, including truncating variants, copy-number changes, and non-truncating variants such as in-frame indels. Molecular and clinical correlations of these variant types remain incompletely defined, particularly for rare deletions. We present two distinct cases highlighting NF2 inactivation spectrum. Case 1 describes a 62-year-old man with a jugular foramen schwannoma harboring a novel somatic NF2 in-frame deletion (c.713_733del, p.Ala238_Tyr244del) resulting in complete Merlin expression loss. Structural modeling predicted FERM-C subdomain destabilization; copy-neutral loss of heterozygosity confirmed biallelic inactivation. Case 2 describes a 55-year-old woman with early-onset bilateral vestibular schwannomas caused by a germline whole-gene NF2 deletion, with additional somatic mutations (splice-site and frameshift) inactivating the second allele. Pedigree analysis demonstrated paternal inheritance, underscoring the relevance of genetic counseling. Both tumors displayed classical schwannoma histology with absent Merlin staining, confirming functional NF2 loss. These cases emphasize the necessity of comprehensive molecular testing-including targeted sequencing, whole-genome sequencing, and multiplex ligation-dependent probe amplification-to detect nucleotide-level and large-scale NF2 alterations; moreover, they expand the NF2 mutation spectrum, illustrate pathogenic mechanisms across germline and somatic contexts, and provide clinically actionable insights for Merlin-deficient tumors.

Indexed as

Germline NF2 deletionNF2-related schwannomatosisVestibular schwannomaWhole-genome sequencing

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.